Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1903-1917
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1903
Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1903
Ref. | Country | NCT number/Name | Variable | Upfront surgery | NAT plus surgery | P value |
Golcher et al[7] | Germany | NCT00335543 | mOS; mo | 14.4 | 17.4 | 0.96 |
Versteijne et al[8] | Netherlands | PREOPANC | mOS; mo | 14.6 | 15.6 | 0.83 |
Casadei et al[9] | Italy | - | mOS; mo | 19.5 | 22.4 | 0.97 |
Reni et al[10] | Italy | PACT-15 | mOS; mo | 20.4,26.4 | 38.2 | NM |
Satoi et al[11] | Japan | Prep-02/JSAP-05 | mOS; mo | 26.6 | 36.7 | 0.015 |
- Citation: Zhang HQ, Li J, Tan CL, Chen YH, Zheng ZJ, Liu XB. Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis. World J Gastrointest Oncol 2022; 14(10): 1903-1917
- URL: https://www.wjgnet.com/1948-5204/full/v14/i10/1903.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i10.1903